$INO: Inovio Receives FDA Accelerated Approval for VOCERYQ in Adult RRP

$INO

$INO – Inovio Receives FDA Accelerated Approval for VOCERYQ in Adult RRP

INOVIO PHARMACEUTICALS, INC.

2026-11-02 00:00:00 UTC · SEC_8K · All $INO

?? Positive AI Sentiment (+8.5 / 10)

FDA grants accelerated approval for VOCERYQ (sifuplasmid-gxfd / INO-3107) for adults with recurrent respiratory papillomatosis (RRP).
Confirmatory trial protocol to be aligned by mid-2027 to confirm clinical benefit.
Commercial availability targeted to begin following approval.